Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: MedImmune's RespiGam

Executive Summary

MedImmune's RespiGam: FDA's Blood Products Advisory Committee will review the PLA for RSV-IVIG product in the prevention of serious respiratory syncytial virus on Dec. 15. MedImmune amended its RespiGam PLA in September. The PLA was previously rejected by the committee. The committee also will meet in closed session at 2 p.m. on Dec. 15. On Dec. 14, in the morning the committee will hear FDA updates on Creutzfeldt-Jakob disease and HIV-1 screening, Trypanosoma cruzi testing of blood donors, and a report of an FDA-HRSA contract study of the U.S. tissue procurement distribution system. On the afternoon of Dec. 14, the committee will hear a summary of a workshop on cord blood and peripheral blood hematopoietic stem cell products intended for transfusion. The meeting begins at 8 a.m. on both days in conference rooms D & E of FDA's Parklawn building in Rockville, Md...

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel